Author

J. Bakar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

B. E. Mendelson· 1 shared D. Bhattacharjee· 1 shared E. L. Sausville· 1 shared J. C. Smith· 1 shared J. M. Sheltzer· 1 shared K. Long· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

B. E. Mendelson

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A drug's most potent target is not necessarily the source of its anti-cancer activity

D. Bhattacharjee, J. Bakar, E. L. Sausville, B. E. Mendelson, K. Long, J. C. Smith, J. M. Sheltzer

This study shows that ralimetinib's anti-cancer effect is due to EGFR inhibition, not p38, and highlights the need for comprehensive profiling to determine drug mechanisms.

Cell Chemical Biology · Oct 1, 2023Peer-reviewedCancer Biology